Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jun 1;146(6):2206-2207.
doi: 10.1093/brain/awad143.

Where have prions been all our lives?

Eric Minikel Vallabh  1   2   3   4 , Sonia M Vallabh  1   2   3   4
Affiliations
Editorial

Where have prions been all our lives?

Eric Minikel Vallabh et al. Brain. .

Erratum in

Abstract

This scientific commentary refers to ‘Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease’ by Mok et al. (https://doi.org/10.1093/brain/awad101).

PubMed Disclaimer

Conflict of interest statement

S.M.V. has received speaking fees from Ultragenyx, Illumina, and Biogen, consulting fees from Invitae, and research support in the form of unrestricted charitable contributions from Ionis, Gate, and Charles River. E.V.M. has received consulting fees from Deerfield and research support in the form of unrestricted charitable contributions from Ionis, Gate, and Charles River.

Figures

Figure 1
Figure 1
Correlation between prodromal period detectable via NfL and disease duration. Neurofilament light (NfL) data from Mok et al. Quiroz et al., Scahill et al. and Benatar et al.; and disease duration data from Minikel et al., Bali et al., Ryman et al. and Langbehn. Data and source code for this figure are available at https://github.com/ericminikel/mok_commentary.
See this image and copyright information in PMC

Comment on

  • Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease.
    Mok TH, Nihat A, Majbour N, Sequeira D, Holm-Mercer L, Coysh T, Darwent L, Batchelor M, Groveman BR, Orr CD, Hughson AG, Heslegrave A, Laban R, Veleva E, Paterson RW, Keshavan A, Schott JM, Swift IJ, Heller C, Rohrer JD, Gerhard A, Butler C, Rowe JB, Masellis M, Chapman M, Lunn MP, Bieschke J, Jackson GS, Zetterberg H, Caughey B, Rudge P, Collinge J, Mead S. Mok TH, et al. Brain. 2023 Jun 1;146(6):2570-2583. doi: 10.1093/brain/awad101. Brain. 2023. PMID: 36975162 Free PMC article.

References

    1. Mok TH, Nihat A, Majbour N, et al. Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease. Brain. 2023;146:2570–2583. - PMC - PubMed
    1. Minikel EV, Vallabh SM, Orseth MC, et al. Age at onset in genetic prion disease and the design of preventive clinical trials. Neurology. 2019;93:e125–e134. - PMC - PubMed
    1. Quiroz YT, Zetterberg H, Reiman EM, et al. Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer’s disease kindred: A cross-sectional and longitudinal cohort study. Lancet Neurol. 2020;19:513–521. - PMC - PubMed
    1. Scahill RI, Zeun P, Osborne-Crowley K, et al. Biological and clinical characteristics of gene carriers far from predicted onset in the huntington’s disease young adult study (HD-YAS): A cross-sectional analysis. Lancet Neurol. 2020;19:502–512. - PMC - PubMed
    1. Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84:130–139. - PMC - PubMed